of depression. 25 SSRIs were further shown to exert their antidepressant effect through an increased level of p11, a regulator protein known to interact with serotonin receptors. SSRIYrelated p11 increases were apparently dependent on signaling by the cytokines interferon-F and tumor necrosis factor (TNF); NSAIDs inhibited the SSRI-induced step-activating cytokines, decreasing the antidepressant response, but did not affect the antidepressant action of TCAs. 25 The authors mention in their discussion that similar findings were noted in a clinical population studied retrospectively. Although the decrease in clinical effectiveness was evident, the mechanism of these interactions is not yet clear, especially because depression has increasingly been associated with an inflammatory state and increased TNF levels. 26Y28 One would, therefore, have expected antidepressants to reduce rather than increase TNF revels. In fact, there is some suggestive evidence that cyclooxygenase 2 inhibitors may have antidepressant actions themselves. 29 The authors further state that TNF may increase brainderived neurotrophic factor (BDNF) that contributes to the antidepressant action. However, the flavonoid luteolin (5,7,3 ¶,4 ¶-tetrahydroxyflavone) prevents human mast cell release of proinflammatory molecules, 30 including TNF ( Fig. 2) , and human mast cellYdependent T-cell activation mediated through TNF. 31 Yet, a close structural analogue of luteolin (7, 8-dihydroxyflavone) can mimic the action of BDNF. 32 Luteolin inhibits microglia with concomitant spatial working memory increases in mice 33 and also protects dopaminergic neurons. 34 These findings are apparently contrary to the hypothesis presented by the authors. One possible explanation may be that luteolin may increase BDNF independently of any action on TNF levels.
Instead of NSAIDs, one may consider the use of certain natural flavonoid compounds 35 that not only do not share any properties with NSAIDs but also have been reported by some to have beneficial actions in animal models of ME/CFS. 36, 37 For instance, epigallocatechin and curcumin were reported to prevent the development of symptoms in a rodent model of ME/CFS. 38, 39 A dietary formulation containing mostly luteolin was presented at a recent National Institutes of Health (NIH)Y sponsored ME/CSF conference (http://www.prohealth.com/library/ showarticle.cfm?libid=16032) and is already being used by patients.
Health providers should be aware of these potential adverse interactions and may prefer to elect non-SSRIs when there is need to administer both antidepressants and analgesics, or choose non-NSAID analgesics, such as tramadol and/or anti-inflammatory flavonoids, as the case is for ME/CFS.
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FIGURE 2. Effect of luteolin on substance PYinduced TNF secretion from cultured human LAD2 mast cells, kindly supplied by Dr A. Kirshembaum (NIH, Bethesda, MD) and grown in StemPro medium (Invitrogen, Carlsbad, CA) and supplemented with stem cell factor, kindly supplied by Biovitrum AB (Stockholm, Sweden). Luteolin dissolved in dimethyl sulfoxide was used at a final concentration of 100 KM for 30 minutes before SP (2 KM), and TNF was measured in the supernatant fluid 24 hours later by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). Viability was higher than 95% (n = 3, *P G 0.05 using Mann-Whitney U test). Spon indicates spontaneous release from control, unstimulated cells.
